Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 18/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 16/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 10/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.44 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7532983 | 0.83 | ACHE (0.55) | SLC6A4OPRM1OPRD1SLC22A1CHRM2 | |
| SCHEMBL3270818 | 0.81 | SLC6A4 (0.49) | SLC6A4SLC6A3SLC6A2OPRM1OPRL1 | |
| SCHEMBL9136443 | 0.81 | ALOX5 (0.45) | SLC6A4OPRM1OPRD1SLC22A1CHRM2 | |
| SCHEMBL3272001 | 0.80 | ICMT (0.53) | SLC6A4SLC6A3SLC6A2OPRM1OPRL1 | |
| SCHEMBL9138011 | 0.74 | OPRD1 (0.63) | OPRM1OPRD1OPRK1 | |
| SCHEMBL14002773 | 0.73 | SLC6A4 (0.50) | SLC6A4SLC6A3SLC6A2OPRM1OPRL1 | |
| SCHEMBL9219871 | 0.73 | OPRD1 (0.44) | SLC6A4SLC6A2OPRM1MEN1OPRD1 | |
| SCHEMBL9250652 | 0.72 | OPRM1 (0.44) | SLC6A4SLC6A2OPRM1OPRL1OPRD1 | |
| SCHEMBL9137028 | 0.71 | ALOX5 (0.44) | OPRM1OPRD1OPRK1 | |
| SCHEMBL1599480 | 0.71 | ALOX5 (0.54) | OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1747210-B1 | 3- OR 4-MONOSUBSTITUTED PHENOL AND THIOPHENOL DERIVATIVES USEFUL AS H3 LIGANDS | WARNER LAMBERT CO (US) | 2010-06-30 | — | — | EP | disclosed |
| US-7456164-B2 | Useful for treatment of H3-related diseases such as neurologic disorders, or inflammatory, respiratory and allergic diseases, disorders and conditions; for example, 4-[4-(1-isopropylpiperidin-4-yloxy)phenyl]tetrahydropyran-4-carbonitrile; well absorbed from gastrointestinal tract, metabolically stable | PFIZER, INC (US) | 2008-11-25 | — | — | US | disclosed |
| EP-1747210-A1 | 3- OR 4-MONOSUBSTITUTED PHENOL AND THIOPHENOL DERIVATIVES USEFUL AS H3 LIGANDS | Warner-Lambert Company LLC (US) | 2007-01-31 | — | — | EP | disclosed |
| US-20050267095-A1 | 3- or 4-monosubstituted phenol and thiophenol derivatives useful as H3 ligands | ZIARCO INC. | 2005-12-01 | — | — | US | disclosed |
| WO-2005108384-A1 | 3- OR 4-MONOSUBSTITUTED PHENOL AND THIOPHENOL DERIVATIVES USEFUL AS H3 LIGANDS | WARNER-LAMBERT COMPANY LLC (US) | 2005-11-17 | — | — | WO | disclosed |
| EP-1593679-A1 | 3- Or 4-monosubstituted phenol derivatives useful as H3 ligands | Warner-Lambert Company LLC (US) | 2005-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267095-A1 | 3- or 4-monosubstituted phenol and thiophenol derivatives useful as H3 ligands | HRH4, HRH3, TLR4 | SLC6A4 2629/4885SLC6A3 2491/4885SLC6A2 3564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.